Listed

Reflect Scientific, Inc.: Form 10-Q for the period ended Sep 30, 2018

Filed with the SEC on Nov 14, 2018 and accepted by EDGAR at Nov 14, 2018, 17:26 ET.

Share

Management's discussion and analysis

As filed, 11,719 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Special Note Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the “Act”) provides a safe harbor for forward-looking statements made by or on behalf of our Company. Our Company and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this Annual Report and other filings with the Securities and Exchange Commission and in reports to our Company’s stockholders. Management believes that all statements that express expectations and projections with respect to future matters, as well as from developments beyond our Company’s control including changes in global economic conditions are forward-looking statements within the meaning of the Act. These statements are made on the basis of management’s views and assumptions, as of the time the statements are made, regarding future events and business performance. There can be no assurance however, that management’s expectations will necessarily come to pass. Factors that may affect forward- looking statements include a wide range of factors that could materially affect future developments and performance, including the following:

Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest;

Changes in U.S., global or regional economic conditions;

Changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company’s access to, or increase the cost of, external financing for our operations and investments;

Increased competitive pressures, both domestically and internationally;

Legal and regulatory developments, such as regulatory actions affecting environmental activities;

The imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls;

Adverse weather conditions or natural disasters, such as hurricanes and earthquakes, labor disputes, which may lead to increased costs or disruption of operations.

This list of factors that may affect future performance and the accuracy of forward-looking statements are illustrative, but by no means exhaustive. Accordingly, all forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited Financial Statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. The Company believes there have been no significant changes during the nine month period ended September 30, 2018, to the items disclosed as significant accounting policies in management's Notes to the Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.

Plan of Operation and Business Growth

Our revenues during the three month reporting periods increased to $359,151 during 2018 compared to 2017 revenues of $325,870, an increase of $33,281, or 10%. Revenues during the nine month reporting periods increased to $1,119,491 during 2018 compared to $880,072 in 2017, an increase of $239,419, or 27%.

Our efforts continue to be focused on increasing the sales of our life science consumables and detectors while, at the same time, working to enhance the design of our liquid nitrogen refrigeration products. Of those liquid nitrogen refrigeration products, the ultra-low temperature freezer is receiving highest priority. We have received positive feedback of the improvements and enhancements made to the design of the ultra-low temperature freezer. We also continue work on the refrigerated trailer, or “reefer.” We have our first manufactured unit operational, have conducted a number of road tests and are working to develop alliances with contract manufacturers for those products.

Concurrent with the development and commercialization of the above products, we have completed our on-line catalog and are making progress in enrolling new distributors for our consumable products.

An analysis of operating results for the three and nine months ended September 30, 2018 follows.

Results of Operations

Three Months Ended September 30, 2018 and 2017

For the three months ended September 30, 2018 2017 Change
Revenues $359,151 $325,870 $33,281
Cost of goods sold 151,178 84,636 66,542
Gross profit 207,973 241,234 (33,261)
Operating expenses 250,090 182,177 67,913
Other expense 456 - 456
Net profit (loss) $(42,573) $59,057 $(101,630)

Revenues increased during the quarter ended September 30, 2018, to $359,151 from $325,870 for the quarter ended September 30, 2017, an increase of $33,281. The primary driver for the sales increase was our purification products, which had sales of $112,722 in 2018 compared to $79,751 in 2017, an increase of $33,021. We are continuing work to increase our market penetration in the specialty lab supplies marketplace while growing our ultra-low temperature freezer product line.

Cost of goods increased in the quarter ending September 30, 2018, as compared to September 30, 2017, to $151,178 from $84,636, an increase of $66,542. The cost of goods increase results from a higher percentage of our sales coming from our specialty laboratory products, which carry lower margins that our ultra-low temperature freezers. We realized a gross profit percentage of 58% for the three months ended September 30, 2018, compared to 74% for the three months ended September 30, 2017. The gross profit percentage is dependent on the mix of product sales, which varies from quarter to quarter. We continue to actively work to obtain more favorable pricing from our vendors in order to increase the margins realized on all product lines.

Operating expenses increased to $250,090 for the three months ended September 30, 2018, an increase of $67,913 over the expenses of $182,177 incurred in the three month period ended September 30, 2017. The increase results primarily from increases in salaries, consulting, stock based compensation, health insurance, and professional fees, offset by small increases in a number of other expense categories. While we continue to monitor and minimize operating costs, we also realize that certain levels of expenditures are required in order to commercialize the products and achieve market penetration.

The net loss for the three month period ended September 30, 2018 was $42,573, compared to a net profit of $59,057 for the three month period ended September 30, 2017. Management continues to look for opportunities to increase sales, improve gross margins and control ongoing operating expenses.

The net loss of $42,573 for the three month period ended September 30, 2018 represents a loss of $(0.00) per share. This compares to the net profit of $59,057, or $0.00 per share, for the three months ended September 30, 2017.

Nine Months Ended September 30, 2018 and 2017

For the nine months ended September 30, 2018 2017 Change
Revenues $1,119,491 $880,072 $239,419
Cost of goods sold 381,015 266,328 114,687
Gross profit 738,476 613,744 124,732
Operating expenses 899,619 543,978 355,641
Other expense 456 - 456
Net profit (loss) $(161,599) $69,766 $(231,365)

Revenues increased during the nine month period ended September 30, 2018, to $1,119,941 from $880,072 for the nine month period ended September 30, 2017, an increase of $239,419. The increase results primarily from the sale of ultra-low temperature freezers which generated revenue of $312,795 in 2018 compared to $170,253 in 2017, an increase of $142,542. We are continuing work to increase our market penetration in the ultra-low temperature freezer market.

With the increase experienced in sales, cost of goods increased in the nine month period ending September 30, 2018, as compared to September 30, 2017, to $381,015 from $266,328, an increase of $114,687. We realized a gross profit percentage of 66% for the nine months ended September 30, 2018, compared to 70% for the nine months ended September 30, 2017. The gross profit percentage is dependent on the mix of product sales, which varies from quarter to quarter. The ultra-low temperature freezers provide higher gross margins than do our laboratory supplies. We continue to actively work to obtain more favorable pricing from our vendors in order to increase the margins realized on all product lines.

Operating expenses increased to $899,619 in the nine months ended September 30, 2018, an increase of $355,641 over the expenses of $543,978 incurred in the nine month period ended September 30, 2017. The increase was primarily the result of a $188,645 non-cash charge for shares of restricted common stock issued for services and a $40,000 non-cash charge for stock-based compensation, as well as increased salary and benefit expenses and increased consulting fee and commission expenses. While we continue to monitor and minimize operating costs, we also realize that certain levels of expenditures are required in order to commercialize the products and achieve market penetration.

The net loss for the nine month period ended September 30, 2018 was $161,599, which compares to a $69,766 profit for the nine month period ended September 30, 2017. Management continues to look for opportunities to increase sales, improve gross margins and control ongoing operating expenses.

The net loss of $161,599 for the nine month period ended September 30, 2018 represents a loss of $0.00 per share. This compares to the net profit of $69,766, or $0.00 per share for the nine months ended September 30, 2017.

Seasonality and Cyclicality

We do not believe our business is cyclical.

Liquidity and Capital Resources

Our cash resources at September 30, 2018, were $178,664, with accounts receivable of $189,989, net of allowance, and inventory of $142,810, net of allowance. Our working capital on September 30, 2018, was $438,728. Working capital on December 31, 2017 was $392,326.

For the nine month period ended September 30, 2018, net cash used by operating activities was $67,371 which compares to $88,607 net cash used by operating activities for the nine month period ended September 30, 2017.

We have a $100,000 line of credit with a commercial bank, which carries a variable rate of interest, which rate is 7.75% at September 30, 2018. In June 2018 we drew $10,750 against this line of credit. The minimum payment on the line is $176 per month. The line may be paid off at any time without penalty. At September 30, 2018, the balance due was $10,177.

Off-Balance Sheet Arrangements

We lease office and warehouse space under a non-cancelable operating lease in Utah. The office lease has been extended through November 30, 2020. Future minimum lease payments under the operating lease at September 30, 2018, are $94,277 for that facility. In addition, on July 7, 2017, the Company entered into an automobile lease with a term of four years. Future minimum lease payments under this lease are $20,757 at September 30, 2018. The lease has an expiration date of July 7, 2021.

Controls and procedures

As filed, 2,103 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(a)

Evaluation of Disclosure Controls and Procedures.

As of the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that information required to be disclosed is recorded, processed, summarized and reported within the specified periods, and is accumulated and communicated to management, including our Chief Executive Officer and Principal Financial Officer, to allow for timely decisions regarding required disclosure of material information required to be included in our periodic Securities and Exchange Commission reports. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and our Chief Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures are not effective at that reasonable assurance level as of the end of the period covered by this report based upon our current level of transactions and staff. However, it should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

(b)

Changes in Internal Control Over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act. Management reviewed our internal controls over financial reporting, and there have been no changes in our internal controls over financial reporting for the nine month period ended September 30, 2018 that have materially affected, or are likely to affect, our internal controls over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-07-01 to 2018-09-30$359.2kus-gaap:Revenues
Revenue9 months2018-01-01 to 2018-09-30$1.1mus-gaap:Revenues
Cost of revenue3 months2018-07-01 to 2018-09-30$151.2kus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2018-01-01 to 2018-09-30$381.0kus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2018-07-01 to 2018-09-30$208.0kus-gaap:GrossProfit
Gross profit9 months2018-01-01 to 2018-09-30$738.5kus-gaap:GrossProfit
Research and development3 months2018-07-01 to 2018-09-30$34.5kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-01-01 to 2018-09-30$49.4kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-07-01 to 2018-09-30−$42.1kus-gaap:OperatingIncomeLoss
Operating income9 months2018-01-01 to 2018-09-30−$161.1kus-gaap:OperatingIncomeLoss
Interest expense3 months2018-07-01 to 2018-09-30−$456us-gaap:InterestExpense
Interest expense9 months2018-01-01 to 2018-09-30−$456us-gaap:InterestExpense
Income tax3 months2018-07-01 to 2018-09-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax9 months2018-01-01 to 2018-09-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-07-01 to 2018-09-30−$42.6kus-gaap:NetIncomeLoss
Net income9 months2018-01-01 to 2018-09-30−$161.6kus-gaap:NetIncomeLoss
Diluted EPS3 months2018-07-01 to 2018-09-30$0.00us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2018-01-01 to 2018-09-30$0.00us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-07-01 to 2018-09-30$0.00us-gaap:EarningsPerShareBasic
Basic EPS9 months2018-01-01 to 2018-09-30$0.00us-gaap:EarningsPerShareBasic
Operating cash flow9 months2018-01-01 to 2018-09-30−$67.4kus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash and equivalentsAt period end2018-09-30$178.7kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-30$535.4kus-gaap:AssetsCurrent
Total assetsAt period end2018-09-30$598.5kus-gaap:Assets
Current liabilitiesAt period end2018-09-30$96.7kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-09-30$96.7kus-gaap:Liabilities
Shareholders' equityAt period end2018-09-30$501.8kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001548123-18-000303. Last ingested by Listed: Oct 24, 2026, 15:01 ET. Listed shows no prices and gives no investment advice.